Abstracts tagged "Cardiovascular disease"

Abstract Number: L04 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Maaman Bashir¹, Katherine Sherman ², Sara K. Tedeschi ³ and Ann Rosenthal ¹, ¹Medical College of Wisconsin, Milwaukee, ²Milwaukee VAMC, Milwaukee, ³Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…
Abstract Number: 900 • 2019 ACR/ARP Annual Meeting
Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
Angelo Gaffo¹, David Calhoun ², Elizabeth Rahn ¹, Suzanne Oparil ², Peng Li ², Tanja Dudenbostel ², David Redden ², Amy Mudano ², Jeffrey Foster ¹, Daniel Feig ², Stephanie Biggers ² and Kenneth Saag ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham
Background/Purpose: An effect of serum urate on vascular endothelium has been postulated as a mechanism for its association with hypertension and cardiovascular disease. Prior studies…
Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Rouhin Sen¹, Sarah Aurit ², Luay Sarsam ³, Osman Bhatty ⁴, Mukund Kumar ¹ and Joseph Nahas ¹, ¹Creighton University Medical Center, Omaha, NE, ²Creighton University Medical Center, Omaha, ³Arnot Health, Elmira, NY, ⁴Montefiore Medical Center Wakefield Campus, Bronx, NY
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…
Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Jon Giles¹, Cecilia Chung ², Mary Chester Wasko ³, Amy Kao ³, Annette Oeser ², C. Michael Stein ² and Joan Bathon ⁴, ¹Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, ²Vanderbilt University, Nashville, TN, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁴Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
Abstract Number: 2136 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DISease (CORDIS)” Study Group of the Italian Society of Rheumatology
Fabio Cacciapaglia¹, Gian Luca Erre ², Garifallia Sakellariou ³, Ombretta Viapiana ⁴, Matteo Piga ⁵, Elena Bartoloni ⁶, Andreina Manfredi ⁷, Sergio Colella ¹, Floriana Castagna ², Giacomo Cafaro ⁸, Martina Dessì ⁵, Marco Fornaro ¹, Alessandro Giollo ⁹, Silvia Grignaschi ¹⁰, Caterina Vacchi ¹¹, Francesca Romana Spinelli ¹², Fabiola Atzeni ¹³ and Elisa Gremese ¹⁴, ¹Rheumatology Unit – Department of Emergency and Organs Transplantation, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Specialità Mediche, Azienda Ospedaliero Universitaria di Sassari, Italy., Sassari, Italy, ³Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴University of Verona, Verona, Italy, ⁵Rheumatology Unit, Department of Medical Sciences, University and AOU Policlinico of Cagliari, Italy., Cagliari, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁷Rheumatology Unit, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Emilia-Romagna, Italy, ⁸Rheumatology Unit, Department of Medicine, University of Perugia, Italy., Perugia, Italy, ⁹Rheumatology Unit, Department of Medicine, University of Verona, Italy., Verona, Italy, ¹⁰Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy., Pavia, Italy, ¹¹Rheumatology Unit, Department of Medical and Surgical Science, University and AOU Policlinico of Modena, Italy., Modena, ¹²Rheumatology, Department of Internal Medicine and Medical Speciality, Sapienza University of Rome, Italy., Rome, Italy, ¹³Rheumatology Unit, University of Messina, Messina, Italy., Messina, Italy, ¹⁴Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients present high cardiovascular (CV) morbidity and mortality. International guidelines suggest estimating CV-risk in these patients,…
Abstract Number: 923 • 2019 ACR/ARP Annual Meeting
First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: Chronic inflammation is linked to increased risk of cardiovascular disease (CVD) in RA that may manifest as venous thromboembolism (VTE) or atherosclerotic CVD (ASCVD).…
Abstract Number: 2316 • 2019 ACR/ARP Annual Meeting
National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014
Shraddha Jatwani¹, Karan Jatwani ², Bikramjit Bindra ³ and Karan Chugh ¹, ¹St. Vincent Evansville, Evansville, ²Mount Sinai West - St Luke’s Hospital, New York, ³Government Medical College & Hospital, Chandigarh, India
Background/Purpose: Rheumatoid arthritis (RA) has been associated with increased cardiovascular mortality. More intensive treatment with a focus on “treat to target” strategies are being developed,…
Abstract Number: 58 • 2019 ACR/ARP Annual Meeting
In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets
Christian Geier¹, Jon Giles ², Gilad Gibor ³, Joan Bathon ² and Robert Winchester ³, ¹Columbia University, New York, NY, ²Division of Rheumatology, Columbia University, New York, NY, ³Columbia University, New York
Background/Purpose: Dendritic cells (DC) are specialized antigen-presenting cells (APC) that have a central role in the initiation of immune responses. However, prior studies showed numeric decreases…
Abstract Number: 955 • 2019 ACR/ARP Annual Meeting
Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study
Tom Hahn ¹, Eric Sayre ², Maria Victoria Goycochea-Robles ³ and Diane Lacaille⁴, ¹Department of Medicine, University of British Columbia, Vancouver, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Unidad de Investigación en Epidemiologia HGR 1, Mexican Institute of Social Security -, Mexico City, Mexico, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Cardiovascular diseases (CVD) are increased in RA and lead to premature mortality. Statins are effective at preventing incidence of, and mortality from, CVD; yet,…
Abstract Number: 2322 • 2019 ACR/ARP Annual Meeting
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Kimberly Liang¹, Yaming Li ¹, Suresh Mulukutla ¹, Steven Reis ¹, Marc Levesque ¹, Donald Jones ¹, Rachel Gartland ¹, Jennifer Avolio ¹, Ali Hakim Shoushtari ¹, Flordeliza Villanueva ¹, Larry Moreland ¹ and Douglas Landsittel ², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, RI
Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of…
Abstract Number: 182 • 2019 ACR/ARP Annual Meeting
Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts
Fenglong Xie ¹, Cynthia Crowson ², Iris Navarro-Millan ³, Monika Safford ³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, ²Mayo Clinic Rochester, Rochester, ³Weill Cornell Medicine, New York, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Cardiovascular (CV) risk estimation across diverse rheumatoid arthritis (RA) cohorts may be challenging given potential heterogeneity in comorbidities and widely varying prevalence of CV…
Abstract Number: 1078 • 2019 ACR/ARP Annual Meeting
Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study
Dionicio Angel Galarza-Delgado ¹, Iris Colunga-Pedraza ², Jose Azpiri-Lopez ², Karla Paola Cuellar-Calderon², Ileana Cecilia Reynosa-Silva ², Marielva Castro-Gonzalez ² and Carolina Marlene Martinez-Flores ², ¹Universidad Autonoma de Nuevo Leon "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Cardiovascular diseases are among the most common comorbidities in patients with rheumatic diseases (RD) and leads them to an overall increase of mortality in…
Abstract Number: 2323 • 2019 ACR/ARP Annual Meeting
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Sicong Huang ¹, Zeling He ¹, Daniel Solomon ², Elena Massarotti ³, Charlotte Golnik ¹, Thany Seyok ¹, Seth Brownmiller ⁴, Tianrun Cai ³, Nicole Yang ³, Laurel Campbell ³, Leanne Barrett ³, Courtney Bibbo ³, Kenneth Pariser ³, Derrick Todd ³, Marcy Bolster ⁴, Marcelo Di Carli ³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Inflammation accounts for much of the excess cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). We hypothesize that increased systemic inflammation leads to…
Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.